^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3-targeted antibody-drug conjugate

    Related drugs:
    1d
    A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types (clinicaltrials.gov)
    P1, N=150, Recruiting, IDEAYA Biosciences
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD276 (CD276 Molecule) • PTK7 (Protein Tyrosine Kinase 7)
    |
    HER-2 negative
    7d
    A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (clinicaltrials.gov)
    P1/2, N=360, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2030 --> Apr 2031 | Trial primary completion date: Feb 2030 --> Apr 2031
    Trial completion date • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • ifinatamab deruxtecan (DS-7300) • opevesostat (MK-5684)
    9d
    A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • YL201
    14d
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=594, Recruiting, BioNTech SE | N=112 --> 594
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    15d
    YL201-INT-102-02: A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (2025-523742-27-00)
    P1/2, N=35, Not yet recruiting, Medilink Therapeutics (Suzhou) Co. Ltd.
    New P1/2 trial
    |
    Tecentriq (atezolizumab) • YL201
    17d
    A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) (clinicaltrials.gov)
    P1/2, N=262, Recruiting, Merck Sharp & Dohme LLC | N=59 --> 262
    Enrollment change
    |
    Imfinzi (durvalumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    18d
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=112, Recruiting, BioNTech SE | N=82 --> 112
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    20d
    A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.
    New P1/2 trial
    |
    cisplatin • carboplatin
    21d
    A Study YL201 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=990, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    YL201
    21d
    A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Hansoh BioMedical R&D Company
    New P3 trial
    |
    docetaxel • AiRuiLi (adebrelimab) • risvutatug rezetecan (GSK5764227)
    22d
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=82, Recruiting, BioNTech SE | N=52 --> 82
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    22d
    QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=466, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • MHB088C